Xlife Sciences AG (SW:XLS) — Market Cap & Net Worth
Market Cap & Net Worth: Xlife Sciences AG (XLS)
Xlife Sciences AG (SW:XLS) has a market capitalization of $122.27 Million (CHF96.71 Million) as of May 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #18425 globally and #184 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xlife Sciences AG's stock price CHF20.70 by its total outstanding shares 5767572 (5.77 Million). Analyse Xlife Sciences AG operating cash flow efficiency to see how efficiently the company converts income to cash.
Xlife Sciences AG Market Cap History: 2022 to 2026
Xlife Sciences AG's market capitalization history from 2022 to 2026. Data shows change from $216.57 Million to $150.94 Million (-19.62% CAGR).
Xlife Sciences AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xlife Sciences AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
221.84x
Xlife Sciences AG's market cap is 221.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.40x
Xlife Sciences AG's market cap is 5.40 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $216.57 Million | $1.03 Million | $14.31 Million | 210.67x | 15.13x |
| 2023 | $363.86 Million | $988.44K | $14.88 Million | 368.11x | 24.45x |
| 2024 | $185.21 Million | $834.88K | $34.28 Million | 221.84x | 5.40x |
Competitor Companies of XLS by Market Capitalization
Companies near Xlife Sciences AG in the global market cap rankings as of May 4, 2026.
Key companies related to Xlife Sciences AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Xlife Sciences AG Historical Marketcap From 2022 to 2026
Between 2022 and today, Xlife Sciences AG's market cap moved from $216.57 Million to $ 150.94 Million, with a yearly change of -19.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF150.94 Million | -16.19% |
| 2025 | CHF180.11 Million | -2.76% |
| 2024 | CHF185.21 Million | -49.10% |
| 2023 | CHF363.86 Million | +68.01% |
| 2022 | CHF216.57 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Xlife Sciences AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $122.27 Million USD |
| MoneyControl | $122.27 Million USD |
| MarketWatch | $122.27 Million USD |
| marketcap.company | $122.27 Million USD |
| Reuters | $122.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more